Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
Business Wire India On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost…